Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Does wegovy work after stopping the medication?

See the DrugPatentWatch profile for wegovy

How Long Does Wegovy Stay Active After Stopping?

Wegovy, brand name for semaglutide, is a medication prescribed for weight management in adults with obesity or weight-related conditions. It's a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the action of natural hormones to help with weight loss.

Does Wegovy Have a Withdrawal Effect?

According to a study published in the International Journal of Obesity, semaglutide has a relatively short half-life of approximately 1.8 hours. This means that its effects on the body should wear off quickly, usually within a few days.

Clinical Data

A clinical trial of Wegovy (Study NCT03623103) found that after stopping semaglutide, patients' weight loss plateaued, but some still maintained a significant portion of their weight loss at 26 weeks post-treatment. This suggests that while Wegovy may not be as effective in maintaining weight loss long-term, some patients may still experience benefits.

Regulatory Approval and Labeling

Wegovy's labeling, as approved by the U.S. Food and Drug Administration (FDA), recommends that patients discontinue treatment if they do not achieve a clinically meaningful weight loss by 20 weeks. However, the labeling does not directly address the duration of semaglutide's effects after stopping treatment.

Patient Concerns and Follow-Up Treatment

It's essential to note that the decision to stop or continue Wegovy treatment should be made in consultation with a healthcare provider. While Wegovy may cease to have a significant impact on weight loss after stopping, other factors, such as lifestyle changes, diet, and exercise, can contribute to sustained weight loss.

[1] International Journal of Obesity: Semaglutide, a Novel GLP-1 Receptor Agonist, for the Treatment of Obesity (Source)

[2] FDA Approval of Wegovy (Semaglutide) Injection for Chronic Weight Management

Sources

1. International Journal of Obesity: [1] Semaglutide, a Novel GLP-1 Receptor Agonist, for the Treatment of Obesity
2. FDA Approval of Wegovy (Semaglutide) Injection for Chronic Weight Management
3. (Source) refers to other cited sources not hyperlinked



Other Questions About Wegovy :

Can Wegovy cause headaches? What's the difference between wegovy and ozempic for weight loss? Does wegovy cause tiredness? What happens if i miss a dose of wegovy? Is wegovy a more cost effective option than ozempic? Can wegovy affect thyroid nodules? Can wegovy cause diarrhea?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy